Pharmaceutical Manufacturing of Racepinephrine Inhalation Solution

The contract pertains to the manufacturing of Racepinephrine Inhalation Solution, USP 2.25%, encompassing all aspects of formulation, quality control, stability testing, and comprehensive batch documentation, with strict adherence to FDA and USP standards. The scope requires full regulatory compliance throughout production to ensure safety, potency, and consistency of the final product, with all processes documented to meet federal pharmaceutical manufacturing requirements. The work must be performed at the designated place of performance in Hampton, Virginia, with a zip code of 23665, and the contract is classified as a subcontract under NAICS code 325412, indicating its alignment with pharmaceutical and medicinal product manufacturing. The solicitation was posted on July 14, 2026, with a response deadline of July 20, 2026, indicating a short turnaround for submissions. The contracting entity is the Department of Defense, specifically under the Medical Supply Chain Pharm FSA, suggesting this product is intended for military or federal healthcare use. There is no set-aside designation specified, meaning the subcontract is open to all qualifying vendors without preference based on business size or status. Interested parties must submit proposals through the DIBBS portal using the provided RFQ link, with no point of contact listed, implying all communications should be directed through the official procurement platform.